Sutent (sunitinib) improves disease-free survival in kidney cancer patients at high risk of recurrence following surgery

Pfizer announced this week that the phase III S-TRAC clinical trial of sunitinib versus placebo in patients with renal cell carcinoma (RCC) who are at hight risk of recurrence after surgery has met its primary endpoint of improving disease-free survival (DFS). The S-TRAC trial is the first RCC trial of a tyrosine kinase inhibitor (TKI) to […]

read more

Nivolumab blocked by NICE for kidney cancer

Disappointing news for kidney cancer patients: the National Institute for Health and Care Excellence (NICE) have issued an interim decision not to recommend the immunotherapy drug nivolumab (Opdivo®) as a second-line treatment for metastatic kidney cancer, despite it’s proven effectiveness at prolonging the life of kidney cancer patients. In their Appraisal Consultation Document (ACD) released […]

read more

Nephrectomy adds benefit to targeted therapies in metastatic kidney cancer

A recent study in America has shown that cytoreductive nephrectomy followed by targeted therapy in patients with metastatic renal cell carcinoma (mRCC) improves survival versus patients treated only with targeted therapies. The study will be published in the Journal of Clinical Oncology on 1 July 2016. The study looked at the use of cytoreductive nephrectomy in combination […]

read more

Could asbestos be a risk factor in kidney cancer as well as mesothelioma?

A new case report published by occupational medicine specialists at the Scientific Institute of Pavia in Italy suggests that asbestos may be linked to the development of renal cell carcinoma. Doctors in Italy have just published the case report of a man who developed kidney cancer after 7 years of asbestos exposure. Just a year later, he […]

read more

Nivolumab plus ipilimumab combo approved by NICE for melanoma

The National Institute for Health and Care Excellence (NICE) has approved a combination of two immunotherapy drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), for the treatment of advanced skin cancer (melanoma). This approval comes within a couple of months of the combination getting a licence. Patients with advanced melanoma in England and Wales will be the first […]

read more

Follow-up data from phase I/II clinical trial with INTUVAX in kidney cancer shows promise

Follow-up data from a phase I/II clinical trial with INTUVAX in eleven patients with metastatic kidney cancer have been announced by Immunicum, a Swedish biopharmaceutical company. The trial was started in February 2012, and 5 patients are still alive. The median overall survival for the entire patient group has more than doubled, and the median overall […]

read more

Take home messages from ASCO

The American Society of Clinical Oncology (ASCO) annual meeting is the biggest cancer conference in the world. This year’s conference took place in Chicago last week, and attracted more than 35,000 cancer researchers, oncologists, patient advocates, politicians and other major players in pharmaceuticals and biotechnology. One of the hottest topics this year was immunotherapy, with […]

read more

Researchers discover a mechanism that reverses TKI drug resistance

Researchers from the Breast Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO) have discovered a resistance mechanism to antiangiogenic drugs, a class of drugs commonly used to treat cancer. They published their findings in the journal Cell Reports recently, where they describe the resistance mechanism to these compounds and, more importantly, a way to […]

read more

Utomilumab for treatment of solid tumours

At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last week, Pfizer presented the results of a dose-escalation study evaluating the overall safety, pharmacokinetics, pharmacodynamics and anti-tumour activity of utomilumab, in combination with pembrolizumab (Keytruda), in patients (n~23) with advanced solid tumours, including non-small cell lung cancer, renal cell carcinoma, head and […]

read more

Nivolumab associated with improved quality of life versus everolimus

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last week, indicated that nivolumab was associated with improvement in health-related quality of life (HRQoL) compared with everolimus in previously treated patients with advanced renal cell carcinoma (RCC). In the phase 3 CheckMate 025 study, previously treated patients with advanced renal […]

read more
Showing 951 to 960 of 998 results
  TOP